Session » Measures and Measurement of Healthcare Quality Poster I

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1094

A Model for Improved Management of Fragility Fractures: Navigating the Fracture Liaison Service

9:00AM-11:00AM: Abstract Number: 1090

A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout

9:00AM-11:00AM: Abstract Number: 1085

Application of Lupus Nephritis Quality Measures to Understand Gaps in Care for SLE

9:00AM-11:00AM: Abstract Number: 1102

Choosing Unwisely: HLA-B27 Testing and Adherence to Choosing Wisely Practices in a Large Integrated Academic Healthcare System

9:00AM-11:00AM: Abstract Number: 1096

Clinical Significance of RNP Antibodies in Diagnosis of Systemic Autoimmune Rheumatic Disease When Detected By Multiplex Immunoassay

9:00AM-11:00AM: Abstract Number: 1100

Communication between Inpatient and Outpatient Specialty Clinicians: Developing a Better Understanding of Patients with Rheumatoid Arthritis Who Are Admitted to the Hospital

9:00AM-11:00AM: Abstract Number: 1093

Effectiveness of the Outreach Model for Rheumatology Specialty Clinics to On-Reserve First Nations in Canada: System-Level and Individual Measures of Performance and Outcomes

9:00AM-11:00AM: Abstract Number: 1080

Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction

9:00AM-11:00AM: Abstract Number: 1084

Emdhaq: (electronic multidimensional health assessment questionnaire) to Record and Document eRAPID3 (electronic routine assessment of patient index data3) and eFAST3 (electronic fibromyalgia assessment screening tool3) in Routine Rheumatology Care

9:00AM-11:00AM: Abstract Number: 1098

Glucose-6-Phosphate Dehydrogenase Testing in a US Veterans Healthcare System: Are We Ordering Unnecessary Tests?

9:00AM-11:00AM: Abstract Number: 1099

Hepatitis B Reactivation in Rheumatologic Patients

9:00AM-11:00AM: Abstract Number: 1081

Improving Patient-Reported Outcomes Collection and Documentation for Patients with Rheumatoid Arthritis at Multilingual, Safety Net Hospital Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1095

Increasing Lipid Panel Monitoring in a Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1078

Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts

9:00AM-11:00AM: Abstract Number: 1097

Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital

9:00AM-11:00AM: Abstract Number: 1089

Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry

9:00AM-11:00AM: Abstract Number: 1082

Responsiveness and Minimally Clinically Important Differences of Promis Measures in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1083

Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes

9:00AM-11:00AM: Abstract Number: 1087

Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals

9:00AM-11:00AM: Abstract Number: 1086

Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1088

Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure

9:00AM-11:00AM: Abstract Number: 1101

Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability

9:00AM-11:00AM: Abstract Number: 1092

The Ottawa Biologics Safety and Screening Tool

9:00AM-11:00AM: Abstract Number: 1091

The Utility of Electronic Consultation in the Management of Gout at the Veterans Affairs Medical Center

9:00AM-11:00AM: Abstract Number: 1103

Towards Recommendations on Functional Assessment Status Measures for Rheumatoid Arthritis: Preliminary Results from a Systematic Review

9:00AM-11:00AM: Abstract Number: 1079

Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].